Glucagon News and Research

RSS

Phase 2 trial reveals Lixisenatide may reduce motor disability in Parkinson’s patients

A trial of lixisenatide to assess its effects in early Parkinson’s disease.

18 Apr 2024

Popular diabetes drugs not linked to thyroid cancer risk, study finds

The complex relationship between obesity and male reproductive function

Authors have analyzed current evidence on the impact of obesity on the male reproduction system.

9 Apr 2024

Treating early-stage heart failure in diabetic patients: Insights from ARISE-HF trial

One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes did not meet its primary endpoint, but a preplanned subgroup analysis found a statistically significant effect of treatment in patients who were not taking SGLT2 inhibitors or GLP-1 RAs, which are antidiabetic medications that also have benefits for the heart.

8 Apr 2024

Can sugar-free biscuits cut appetite in overweight adults? New study explores

The changes in endocrine responses and appetite with sweeteners and sweetness enhancers such as Stevia and Neotame.

2 Apr 2024

Sweeteners do not increase hunger and help lower blood sugar, study finds

Replacing sugar with artificial and natural sweeteners in foods does not make people hungrier – and also helps to reduce blood sugar levels, a significant new study has found.

28 Mar 2024

Weight loss drugs associated with increased risk of aspiration pneumonia following endoscopy

New research from Cedars-Sinai suggests people who are scheduled for certain medical procedures should stop taking popular weight loss drugs in the days or weeks prior to avoid complications.

27 Mar 2024

AI-based analysis uncovers two plant extracts with potential as GLP-1 agonist weight loss pills

Two plant compounds with potential as GLP-1 agonist weight loss pills have been identified in an AI (artificial intelligence)-based study, the European Congress on Obesity (ECO 2024) (Venice 12-15 May), will hear.

26 Mar 2024

Microneedles offer a promising solution for the treatment of diabetic wounds

The global population of patients with diabetic wounds is expected to rise to between 9.1 million to 26.1 million by 2030.

20 Mar 2024

New research sheds light on how GLP-1 obesity drugs may change food cravings

GLP-1 analog treatments potentially alter food preferences and reduce obesity by decreasing appetite and food consumption, with further research needed for long-term weight maintenance using objective measures.

10 Mar 2024

Diabetes drug dulaglutide may reduce symptoms of depression

The current study highlighted the antidepressant effects of dulaglutide using the CMS depression model. Notably, the potential metabolisms that underlie the antidepressant effect of dulaglutide have been elucidated in this study.

8 Mar 2024

Study reveals mechanisms behind antidepressant effects of diabetes drug

Research in animals has shown that the diabetes drug dulaglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist may reduce symptoms of depression.

6 Mar 2024

New hope for binge eating and bulimia: GLP-1 drugs could be the key

GLP-1 receptor agonists show promise in reducing binge eating behaviors in disorders like bulimia nervosa, offering a new avenue for treatment with minimal side effects.

4 Mar 2024

Gut bacteria diversity linked to body weight, athletes show healthier profiles

Systematic review reveals gut microbiome variations correlate with body composition changes across lifespan, highlighting differences between obese individuals and athletes.

29 Feb 2024

Exercise, GLP-1 receptor agonist, or combined approach explored in year-long study

Researchers compare the extent of weight loss after one-year termination of active intervention with GLP-1 receptor agonist, exercise, or combination.

29 Feb 2024

Innovative MicroGlucagon solution aims to transform insulin therapy for type 1 diabetics

Researchers in Trondheim are developing a new medicine for diabetics who have to have daily injections of insulin. The key is a hormone that causes the smallest blood vessels to relax on the inside.

22 Feb 2024

AMG 133 (maridebart cafraglutide) weight loss drug shows promise in early trial

AMG 133, an engineered bispecific molecule, demonstrated significant weight loss with a favorable safety profile in a phase 1 clinical trial, offering a promising new treatment option for obesity.

7 Feb 2024

New weight loss drug may be an effective strategy for preventing or treating high blood pressure

The new weight loss medication tirzepatide significantly lowered the systolic blood pressure (the top number in a blood pressure reading) for nearly 500 adults with obesity who took the medication for about eight months, according to new research published today in Hypertension, an American Heart Association journal.

5 Feb 2024

What does the future hold for obesity medication development?

The safety, clinical implications, and challenges of obesity pharmacotherapies based on entero-pancreatic hormone- treatments.

5 Feb 2024

Breakthrough obesity treatments on the horizon, rivaling surgery's success

New obesity pharmacotherapies, including GLP-1 receptor agonists and combinations of entero-pancreatic hormones, show promise in achieving significant weight loss, potentially rivaling bariatric surgery's effectiveness.

4 Feb 2024